Abstracts tagged "Disease Activity"

Abstract Number: 1470 • 2016 ACR/ARHP Annual Meeting
Moderate to Severe Disease Activity in Rheumatoid Arthritis Is Associated with Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake
Isabelle Amigues¹, Jon T. Giles², Afshin Zartoshti³, Rachelle Morgenstern⁴, Raul Flores⁵, Sabahat Bokhari⁶ and Joan Bathon⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁴Cardiology, columbia university college of physicians and surgeons, New York city, NY, ⁵Medicine, Columbia University, New York Presbyterian, New York city, NY, ⁶Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: RA patients are at increased risk for developing heart failure (HF) even after controlling for coronary artery disease (CAD), indicating that factors other than…
Abstract Number: 1700 • 2016 ACR/ARHP Annual Meeting
Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease…
Abstract Number: 2044 • 2016 ACR/ARHP Annual Meeting
Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus
Amanda M. Eudy^1,2, Anna Maria Siega-Riz², Stephanie Engel², Nora Franceschini², Annie Green Howard³, Megan E. B. Clowse¹ and Michelle Petri⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There are conflicting results about the effect pregnancy has on the health of systemic lupus erythematosus (SLE) women. The objective of the current analysis…
Abstract Number: 2508 • 2016 ACR/ARHP Annual Meeting
Significant Improvement of Rheumatoid Arthritis (RA) Outcome with Repeat Application of Disease Management (SSDM) Mobiles Tools: A Cohort Study of RA Patients in China
Jing Yang¹, Hongzhi Wang², Wenqiang Fan³, Hua Wei⁴, Xinwang Duan⁵, Rong Mu⁶, Yu Zhang¹, Xiafei Xin⁷, Jinmei Zou¹, Xiaofeng Li⁸, Jie Wu⁹, Xiaomei Li¹⁰, Guosheng Wang¹¹, Hong Liu¹, Fei Xiao¹², Hui Xiao¹², Yuhua Jia¹², Yuan Liu¹², Bing Wu¹² and Xiaofeng Zeng¹³, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁴No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁵Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Ningbo First Hospital, Zhejiang, Ningbo, China, ⁸The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China, ⁹Central Hospital of XinXiang, Henan, XinXiang, China, ¹⁰Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹¹Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹²Gothic Internet Technology Corporation, Shanghai, China, ¹³Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-Target (T2T) strategy are critical for the treatment…
Abstract Number: 2769 • 2016 ACR/ARHP Annual Meeting
Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?
Gokce Kenar¹, Handan Yarkan², Berrin Zengin¹, Gerçek Can², Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a…
Abstract Number: 3031 • 2016 ACR/ARHP Annual Meeting
Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?
Dennis Lendrem¹, Nadia Howard Tripp^2,3, Xavier Mariette⁴, Svein Joar A. Johnsen⁵, Jessica Tarn⁶, Katie Hackett⁶, Bridget Griffiths⁷, Sheryl Mitchell⁸, Alain Saraux⁹, Valerie Devauchelle¹⁰, Katrine Norheim¹¹, John D. Isaacs¹², Peter McMeekin^13,14, Simon Bowman¹⁵, Roald Omdal¹⁶, Jacques-Eric Gottenberg¹⁷ and Wan-Fai Ng¹⁸, ¹Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ³Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom, ⁴Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁵Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁶Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁷Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ⁸Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁹Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁰Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ¹¹Stavanger University Hospital, Stavanger, Norway, ¹²Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom, ¹³Institute of Health and Society, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ¹⁴Northumbria University, Newcastle-upon-Tyne, United Kingdom, ¹⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ¹⁶University of Bergen, Bergen, Norway, ¹⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁸Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary SjšgrenÕs Syndrome (pSS) is a chronic autoimmune rheumatic disease causing a wide-range of symptoms including dryness, pain and fatigue. Individual patient experiences of…
Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting
Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4
James Gwinnutt¹, Deborah P.M. Symmons^1,2, Alex J Macgregor^3,4, Jacqueline Chipping^3,4, Tarnya Marshall^3,4, Mark Lunt¹ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁴School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom
Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
Abstract Number: 511 • 2016 ACR/ARHP Annual Meeting
Complement C3 and C4 Levels and Its Correlation with Disease Activity in Rheumatoid Arthritis Patients
Julia Sosa¹, Silvia Beatriz Papasidero², María Alejandra Medina¹, Diana Klajn³, Rafael Chaparro del Moral², José Angel Caracciolo⁴, Luciana Casalla⁵, Lucía Zárate⁵, Nieves Capozzi⁵, Josefina Marcos⁶, Mercedes Argentina García⁶, Ana Quinteros⁷, Maria Olga Leal⁷, Dora Lia Vásquez⁷, María Inés Stancich⁸, Analia Alvarez⁹, Carolina Sanchez Andía⁹, Karin Kirmayr¹⁰, María de los Ángeles Correa¹¹ and A. Constantino¹², ¹Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Rheumatology Department, Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Research Committee, Research Committee, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁴Rhematology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁵Rheumatology Section, Hospital Posadas, Buenos Aires, Argentina, ⁶Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ⁷Centro Integral De Reumatologia, Tucumán, Argentina, ⁸Rheumatology Department, Hospital Nacional De Clínicas, Córdoba, Argentina, ⁹Rheumatology Department, Hospital Penna, Buenos Aires, Argentina, ¹⁰Rheumatology Department, Sanatorio San Carlos, Buenos Aires, Argentina, ¹¹Rheumatology Department, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹²Hospital Nacional De Clínicas, Córdoba, Argentina
COMPLEMENT C3 AND C4 LEVELS AND ITS CORRELATION WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS Background/Purpose: Cytokines play a major role in the pathogenesis…
Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting
Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform
Chaim Putterman¹, Pennina Safer², Keren Jakobi², Rachel Sorek², Ilana Gilkaite², Kyle Ferber³, Steve Wallace³, Amanda Harris Altice³, D. Scott Batty³ and Irun R Cohen^2,4, ¹Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray LTD, Rehovot, Israel, ³ImmunArray Inc., Richmond, VA, ⁴Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
Abstract Number: 1471 • 2016 ACR/ARHP Annual Meeting
Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment
Isabelle Amigues¹, Jon T. Giles², Afshin Zartoshti³, Rachelle Morgenstern⁴, Raul Flores⁵, Sabahat Bokhari⁶ and Joan Bathon⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁴Cardiology, columbia university college of physicians and surgeons, New York city, NY, ⁵Medicine, Columbia University, New York Presbyterian, New York city, NY, ⁶Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Symptomatic heart failure (HF) and HF-associated mortality rates are higher in RA compared with the non-RA population, even after controlling for coronary artery…
Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Agnes Szentpetery¹, Natsumi Ikumi¹, Brian Kirby² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
Abstract Number: 2082 • 2016 ACR/ARHP Annual Meeting
Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Jianlin Huang¹, Hongzhi Wang², Jing Yang³, Wenqiang Fan⁴, Hua Wei⁵, Rong Mu⁶, Xinwang Duan⁷, Xiangyuan Liu⁸, Fang He⁹, Zhenchun Zhang¹⁰, Fei Xiao¹¹, Hui Xiao¹¹, Yuhua Jia¹¹, Yuan Liu¹¹, Li Zhang¹¹, Bing Wu¹¹ and Xiaofeng Li¹², ¹Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁸Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ⁹Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁰People's Hospital of Linyi, Shandong, Linyi, China, ¹¹Gothic Internet Technology Corporation, Shanghai, China, ¹²The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-target (T2T) is a widely accepted cretria as…
Abstract Number: 2518 • 2016 ACR/ARHP Annual Meeting
Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
Nicola J Gullick¹, Fowzia Ibrahim², Aneela Mian¹, Alexandra Vincent³, Gabriel Panayi¹, Brian Tom⁴, David L. Scott¹ and Bruce Kirkham³, ¹Rheumatology, King's College London, London, United Kingdom, ²Academic Rheumatology Dept, King's College London, London, United Kingdom, ³Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
Background/Purpose: There has been increasing emphasis on intensive treatment of RA but little direct evidence of the impact of such strategies on long term outcome.…
Abstract Number: 2780 • 2016 ACR/ARHP Annual Meeting
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.